Nektar will take on technology development, while Baxter will handle product development and commercialization.
Nektar Therapeutics reports an agreement with subsidiaries of Baxter International to develop new PEGylated therapeutics for hemophilia. The program is expected to begin preclinical development in 2008.
Nektar will receive up to $44 million in upfront and milestone payments, funding of R&D, and manufacturing revenues during research, clinical development, and commercialization. Nektar will also receive royalties on end product sales.
Baxter will be responsible for the development and commercialization of the product. Nektar will handle the technology development used in the product including the provision of clinical and commercial PEG reagents.
This is the second collaboration between Nektar and Baxter related to hemophilia. The two companies inked their initial agreement in September of 2005 to develop PEGylated therapeutic forms of clotting proteins to treat hemophilia A.